Comparative effect of antihypertensive therapy on blood glucose level in hypertensive patients in an Indian population

Drug Research

Volumn 64, Issue 5, 2014, Pages 276-280

  Ahmad, M A ^a   Kapur, P ^b   Khanam, R ^a   Akhtar, M ^a   Khan, G H ^a   Anwar, M J ^a   Vohora, D ^a  

^a HAMDARD UNIVERSITY   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

ACEIs; ARBs; beta blockers; CCBs; diabetes mellitus; hypertension; impaired glucose tolerance; thiazide

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; METOPROLOL; NEBIVOLOL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; VERAPAMIL; GLUCOSE BLOOD LEVEL;

ABSENCE OF SIDE EFFECTS; ADULT; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; COMPARATIVE EFFECTIVENESS; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INCIDENCE; INDIAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; SEX RATIO; TREATMENT DURATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VERY ELDERLY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; INDIA; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; INDIA; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84899978787     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1357202     Document Type: Article

References (24)

1. Akiko Y., Mikio A., Machi F. et al. The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Diabetes research and clinical practice A.: 2008; 3 127 131
2. Barzilay J. I., Pressel S., Davis B. R. et al. Risk and impact of incident glucose disorder in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: a report from the ALLHAT trial. Am J Hypertens: 2004; 17 1A 1A
3. Chaturvedi M., Jindal S., Kumar R. Lifestyle Modification in Hypertension in the Indian Context. JIACM: 2009; 10 46 51
4. Cooper-DeHoff R. M., Pacanowski M. A., Pepine C. J. Cardiovascular Therapies and Associated Glucose Homeostasis. Journal of the American College of Cardiology: 2009; 53 29 35
5. Curb J. D., Pressel S. L., Cutler J. A. et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. J Am Med Assoc: 1996; 276 1886 1892 (Pubitemid 26419185)
6. Elliott W. J., Meyer P. M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet: 2007; 369 201 207 (Pubitemid 46111014)
7. Ellison D. H., Loffing J. Thiazide Effects and Adverse Effects, Insights From Molecular Genetics. J American Heart Association: 2009; 54 196 202
8. Hansson L., Lindholm L. H., Niskanen L. et al. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet: 1999; 353 611 616 (Pubitemid 29087980)
9. Huen S. C., Goldfarb D. S. Adverse Metabolic Side Effects of Thiazides: Implications for Patients with Calcium Nephrolithiasis. American Urological Association: 2007; 177 1238 1245
10. Kazumi T., Hozumi T., Ishida Y. et al. Effect of nifedipine retard on glucose-induced insulin response in patients with and without Non-insulin-dependent diabetes mellitus and hypertension. Current therapeutic research: 1998; 59 80 91
11. Koh K. K., Quon M. J., Han S. H. et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. International Journal of Cardiology: 2008; 20 30 38
12. Kurtz T. W., Pravenec M. Antidiabetic mechanisms of angiotensin- converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the reninangiotensin system. J Hypertension: 2004; 22 2253 2261 (Pubitemid 39625096)
13. Lindholm L. H., Samuelsson O. Clinical relevance of glucose metabolism disturbances induced by antihypertensive drugs. J European Heart: 2004; 6 31 35
14. Makita S., Abiko A., Naganuma Y. et al. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism Clinical and Experimental: 2008; 57 1473 1478
15. Niskanen L., Hedner T., Hansson L. et al. For the CAPPP Study Group A subanalysis of the Captopril Prevention Project. Diabetes Care: 2001; 24 543 655
16. Pedersen C. T., Metra M., Charlesworth A. et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure, data from the Carvedilol Or Metoprolol European Trial (COMET). Heart: 2007; 93 968 973 (Pubitemid 47122050)
17. Pfeffer M. A., Swedberg K., Granger C. B. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet: 2003; 362 759 766 (Pubitemid 37093915)
18. Siegel D., Swislocki A. L. Effects of Antihypertensives on glucose metabolism. Metabolic Syndrome and Related Disorders: 2007; 5 211 218
19. Sowers J. R., Bakris G. L. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med: 2000; 342 969 970 (Pubitemid 30177059)
20. Stump C. S., Hamilton M. T., Sowers J. R. Effect of Antihypertensive Agents on the Development of Type 2 Diabetes Mellitus. Mayo Foundation for Medical Education and Research: 2006; 81 796 806 (Pubitemid 43841735)
21. Wright J. M., Musini V. M. First-line drugs for hypertension, John Wiley and sons: 2009; 32 232 243
22. Yusuf S., Teo K., Anderson C. et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet: 2008; 372 1174 1183
23. Leo N., Thomas H., Lennart H. et al. Reduced Cardiovascular Morbidity and Mortality in Hypertensive Diabetic Patients on First-Line Therapy with an ACE Inhibitor Compared with a Diuretic/β-Blocker-Based Treatment Regimen. Diabetes Care: 2001; 24 2091 2096
24. John L. Leahy, Susan Bonner-Weir, Gordon C. Weir. (3-Cell Dysfunction Induced by Chronic Hyperglycemiq. DIABETES CARE: 1992; 15 442 455